Tigermed Receives 2020 Chinese Contract Research Organizations Customer Value Leadership Award from Frost & Sullivan
June 2, 2020
HANGZHOU, China, June 2, 2020 — Tigermed, a leading Contract Research Organization (CRO) in China dedicated to provide full comprehensive services and solutions for biopharmaceutical research and development, today announced that it received the 2020 Chinese Contract Research Organizations Customer Value Leadership Award from Frost & Sullivan.
Each year, Frost & Sullivan presents this award to the company that demonstrates excellence in implementing strategies that proactively create value for its customers, with a focus on improving the return on investment that customers make in its services or products. The award recognizes the company’s unique focus on augmenting the value that its customers receive, beyond simply good customer service, leading to improved customer retention and customer base expansion.
Tigermed was recognized by Frost & Sullivan for its stellar track record, expertise, and commitment to service and social responsibility, whose comprehensive service portfolio and robust infrastructure cement its status as a strategic partner for the pharmaceuticals industry.
“Tigermed has been steadily developing its expertise and service portfolio to align with a more complex global clinical trial and regulatory landscape,” said Khushbu Jain, Industry Analyst at Frost & Sullivan. “With a proven track record of taking drugs to market, regulatory compliance on par with international standards, and service excellence, Tigermed continues to grow. Its patient-centric and partner-focused framework is expected to keep it at the forefront of the Chinese CRO market in the coming years.”
According to the Frost and Sullivan Best Practices Award report, Tigermed’s response to the COVID-19 pandemic truly exemplifies its commitment to service, social responsibility, and patients, accelerating potentially life-saving therapies to market. “Tigermed answered the Human Genetic Resources Administration of China’s (HGRAC) call-to-action and became involved in clinical trials. Tigermed’s continuous improvement cycle, alongside customer needs and market trends, is leading it into the next stage of the evolving CRO market.”
“We are honored to be recognized by Frost & Sullivan,” said Xiaochun Cao, Co-founder, Executive Director and General Manager of Tigermed. “Since our inception in 2004, we have always been committed to supporting our clients in the best possible way to address the unmet medical needs. We will continue to excel in clinical trials for the benefit of our clients and patients worldwide by providing services with fundamental principles like quality, innovation, integrity, and ethical conduct at the core of everything we do.”
The Frost & Sullivan Best Practices Award report can be found here.
Hangzhou Tigermed Consulting Co., Ltd（stock code: 300347）is a leading Contract Research Organization (CRO) in China dedicated to provide full comprehensive services and solutions for biopharmaceutical research and development. Since inception in 2004, Tigermed has always embraced state-of-the-art technologies and has engaged in partnerships to accelerate medical product development with costs efficiency and high quality.
Headquartered in Hangzhou, Tigermed operates over 60 subsidiaries and over 100 offices across China, and 13 overseas offices in US, Switzerland, Korea, Australia, Japan, Malaysia, Singapore, India, Canada and Romania with over 5,000 full time employees.